Table 4.
Adjusted Absolute Risk for CIN2 or Higher and CIN3 or Higher Based on HPV Detection in Patients by Onclarity, 30 Years or Older, With NILM Cytology
| Characteristic | Age Group, % (95% CI) | |||
|---|---|---|---|---|
| 30-39 y (n = 8,663) | 40-49 y (n = 6,829) | ≥50 y (n = 6,792) | Overall (n = 22,284) | |
| ≥CIN2 | ||||
| Overall HPV | 7.7 (5.7-10.1) | 3.2 (1.6-5.0) | 1.5 (0.3-3.0) | 5.1 (3.9-6.3) |
| HPV 16 | 14.1 (7.2-22.8) | 6.3 (0.0-13.6) | 2.9 (0.0-7.3) | 9.3 (5.5-13.7) |
| HPV 18 | 6.5 (0.0-16.2) | 0.0 (0.0-0.0) | 5.0 (0.0-15.8) | 3.9 (0.0-8.4) |
| HPV 45 | 2.2 (0.0-7.5) | 3.2 (0.0-10.5) | 0.0 (0.0-0.0) | 2.2 (0.0-5.4) |
| HPV 16/18 | 12.6 (6.8-19.9) | 4.6 (0.0-10.0) | 3.4 (0.0-7.5) | 8.1 (5.0-11.6) |
| HPV 18/45 | 3.9 (0.0-8.7) | 1.7 (0.0-5.7) | 2.8 (0.0-9.2) | 2.9 (0.6-5.5) |
| HPV 16/18/45 | 10.3 (5.7-16.1) | 4.2 (0.8-8.6) | 2.9 (0.0-6.4) | 6.8 (4.4-9.7) |
| Other 11 hrHPV | 6.6 (4.6-8.7) | 2.8 (1.1-4.8) | 0.9 (0.0-2.4) | 4.3 (3.1-5.5) |
| HPV negative | 0.6 (0.0-1.4) | 0.4 (0.0-1.1) | 0.7 (0.0-1.6) | 0.5 (0.1-1.0) |
| ≥CIN3 | ||||
| Overall HPV | 4.2 (2.9-5.7) | 2.2 (0.8-3.8) | 1.2 (0.3-2.5) | 3.0 (2.1-3.9) |
| HPV 16 | 9.0 (4.6-14.0) | 6.3 (0.0-13.6) | 2.9 (0.0-7.3) | 6.9 (3.9-9.9) |
| HPV 18 | 3.2 (0.0-10.3) | 0.0 (0.0-0.0) | 5.0 (0.0-15.8) | 2.6 (0.0-6.4) |
| HPV 45 | 0.0 (0.0-0.0) | 3.2 (0.0-10.5) | 0.0 (0.0-0.0) | 1.1 (0.0-3.4) |
| HPV 16/18 | 7.9 (4.1-12.0) | 4.6 (0.0-10.0) | 3.4 (0.0-7.5) | 5.9 (3.5-8.4) |
| HPV 18/45 | 1.3 (0.0-4.1) | 1.7 (0.0-5.7) | 2.8 (0.0-9.2) | 1.7 (0.0-3.8) |
| HPV 16/18/45 | 6.1 (3.2-9.3) | 4.2 (0.8-8.6) | 2.9 (0.0-6.4) | 4.9 (3.0-6.9) |
| Other 11 hrHPV | 3.4 (2.0-5.1) | 1.4 (0.3-2.9) | 0.5 (0.0-1.5) | 2.2 (1.4-3.2) |
| HPV negative | 0.3 (0.0-0.9) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 0.1 (0.0-0.3) |
CI, confidence interval; CIN2, cervical intraepithelial neoplasia grade 2; CIN3, cervical intraepithelial neoplasia grade 3; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus; NILM, negative for intraepithelial lesion or malignancies.